Cargando…

WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers

Wild-type Wilms' tumor gene WT1 is expressed at a high level in hematopoietic malignancies including acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndromes, as well as in various kinds of solid cancers. Human cytotoxic T lymphocytes (CTLs), which could specifically lyse WT1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oka, Yoshihiro, Tsuboi, Akihiro, Elisseeva, Olga A., Nakajima, Hiroko, Fujiki, Fumihiro, Kawakami, Manabu, Shirakata, Toshiaki, Nishida, Sumiyuki, Hosen, Naoki, Oji, Yusuke, Kawase, Ichiro, Sugiyama, Haruo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2007
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901323/ https://www.ncbi.nlm.nih.gov/pubmed/17619750 http://dx.doi.org/10.1100/tsw.2007.119

Ejemplares similares

Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments
por: Nishida, Sumiyuki, et al.
Publicado: (2019)

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
por: Tsuboi, Akihiro, et al.
Publicado: (2018)

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer
por: Nishida, Sumiyuki, et al.
Publicado: (2022)

WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine
por: Alzaaqi, Shouq, et al.
Publicado: (2022)

Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine
por: Takashima, Satoshi, et al.
Publicado: (2016)

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms
por: Tatsumi, Naoya, et al.
Publicado: (2015)

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides
por: Nakata, Jun, et al.
Publicado: (2018)

Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT
por: Nakata, Jun, et al.
Publicado: (2020)

Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity
por: Morimoto, Soyoko, et al.
Publicado: (2018)

An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells
por: Hasegawa, Kana, et al.
Publicado: (2015)

T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy
por: Fujiki, Fumihiro, et al.
Publicado: (2022)

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1
por: Oji, Yusuke, et al.
Publicado: (2023)

Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs
por: Fujiki, Fumihiro, et al.
Publicado: (2023)

Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis
por: Hasegawa, Kana, et al.
Publicado: (2016)

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer
por: Nishida, Sumiyuki, et al.
Publicado: (2014)

Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth
por: Oji, Yusuke, et al.
Publicado: (1999)

Imaging Assessment of Tumor Response in the Era of Immunotherapy
por: Nakata, Jun, et al.
Publicado: (2021)

IMT-07 CLINICAL TRIAL OF A COCKTAIL WILMS’ TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE FOR RECURRENT MALIGNANT GLIOMAS
por: Kagawa, Naoki, et al.
Publicado: (2019)

Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
por: Minagawa, Hikaru, et al.
Publicado: (2023)

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
por: Nakagawa, Natsuki, et al.
Publicado: (2022)

Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review
por: Hashii, Yoshiko, et al.
Publicado: (2020)

The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers
por: OJI, YUSUKE, et al.
Publicado: (2014)

WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE
por: Narita, Miwako, et al.
Publicado: (2010)

Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma
por: Andersson, Charlotta, et al.
Publicado: (2014)

Distinct difference in tumor-infiltrating immune cells between Wilms’ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies
por: Yokota, Chisato, et al.
Publicado: (2021)

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine
por: Maeda, T, et al.
Publicado: (2013)

The Wilms' Tumor Gene WT1 − 17AA/− KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model
por: Yamanouchi, Keiko, et al.
Publicado: (2014)

Serum WT1-271 IgM antibody as a novel diagnostic marker for Gastric Cancer
por: Ito, Masaaki, et al.
Publicado: (2022)

The Detection of Immunity against WT1 and SMAD4(P130L) of EpCAM(+) Cancer Cells in Malignant Pleural Effusion
por: Koya, Terutsugu, et al.
Publicado: (2022)

Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
por: Ueda, Yasunori, et al.
Publicado: (2017)

Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer
por: Lee, Shing Fung, et al.
Publicado: (2021)

Healing of buccal gingival recessions following treatment with coronally advanced flap alone or combined with a cross‐linked hyaluronic acid gel. An experimental study in dogs
por: Shirakata, Yoshinori, et al.
Publicado: (2021)

Anxiolytic Effect of Aromatherapy Massage in Patients with Breast Cancer
por: Imanishi, Jiro, et al.
Publicado: (2009)

Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine
por: Shirakawa, Toshiro, et al.
Publicado: (2017)

WT1 peptide analogue WT1-126Y enhances leukemia lysis
por: Alqudaihi, Ghofran, et al.
Publicado: (2014)

FGFR1 and WT1 are markers of human prostate cancer progression
por: Devilard, Elizabeth, et al.
Publicado: (2006)

Isolating $Wt$ production at the LHC
por: White, Chris D., et al.
Publicado: (2009)

WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1
por: Lv, Long, et al.
Publicado: (2015)

Fabrication and wear behaviour of Mg-3wt.%Al-x wt. % SiC composites
por: Jayasathyakawin, S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_to15050m7s6a6l4pin6brrbpe3